Adashek, Jacob J. http://orcid.org/0000-0003-4272-312X
Kurzrock, Razelle http://orcid.org/0000-0003-4110-1214
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (5UG1CA233198-05, 5U01CA180888-08)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 27 July 2023
Accepted: 17 November 2023
First Online: 8 December 2023
Competing interests
: Jacob J. Adashek serves on the advisory board of CureMatch Inc and as a consultant for datma. Razelle Kurzrock has received research funding from Biological Dynamics, Boehringer Ingelheim, Debiopharm, Foundation Medicine, Genentech, Grifols, Guardant, Incyte, Konica Minolta, Medimmune, Merck Serono, Omniseq, Pfizer, Sequenom, Takeda, and TopAlliance; as well as consultant and/or speaker fees and/or advisory board for Actuate Therapeutics, AstraZeneca, Bicara Therapeutics, Biological Dynamics, Caris, Daiichi Sankyo, Inc., Datar Cancer Genetics, EISAI, EOM Pharmaceuticals, Iylon, LabCorp, Merck, NeoGenomics, Neomed, Pfizer, Prosperdtx, Roche, TD2/Volastra, Turning Point Therapeutics, X-Biotech; has an equity interest in CureMatch Inc., CureMetrix, and IDbyDNA; serves on the Board of CureMatch and CureMetrix,and is a co-founder of CureMatch.